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Abstract
Background: Trastuzumab has revolutionized the way we treat early Her2Neu-positive breast cancer, as it
significantly improves disease-free and overall survival. Little is known about the societal costs and benefits of
treatment with trastuzumab in the adjuvant setting in Southeast Asia.
Methods: Societal costs (benefits) were estimated as the sum of direct and indirect costs minus benefits in the
base case. Direct costs were derived from 4 treatment centers in Singapore (2 private and 2 public, comprising 60-
70% of all patients with cancer seen in the island-nation); indirect costs were assessed as the loss of productivity
caused by the disease or treatment. Benefits to society were based on extra years of productivity, as measured by
GNI per capita, resulting from the quality adjusted life-years (QALYs) saved with the use of trastuzumab as
determined in the models by Kurian, Liberato and Garrison.
Results: Incremental costs in Singapore, in 2005 US dollars, were $26,971.05. Average Cost per QALY was
$19,174.59 (Median: $18,993.70). Costs (benefits) to society ranged from a cost of $79.42 to a benefit of $9,263.06,
depending on the model used (Average benefit: $4,375.89, Median $3,944.03). Sensitivity analysis ranged from a
cost of $10,685.00 to a Benefit of US$17,298.79
Conclusions: Treatment with adjuvant trastuzumab is likely to generate net societal economic benefits in
Singapore. Nevertheless, the lower range of possible outcomes does not refute the possibility that treatment may
actually generate costs. These costs however clearly fall within the usual range of acceptable cost-effectiveness.
Background
Breast cancer is a major health care problem in Singapore
and worldwide. The most common cancer in women in
industrialized nations, it accounted for approximately
209,060 cases and 40,230 deaths in the United States in
2010 and 1.38 million cases and 458,400 deaths across the
globe in 2008 [1,2]. In Singapore, annually, 1,100 women
develop breast cancer and 270 die from the disease [3].
Major advances have been made in the prevention and
treatment of patients with breast cancer in the last 2 dec-
ades. Currently more than 90% of patients survive for 5
years or greater after their diagnosis, compared to 75% or
fewer 30 years ago [1].
Newer anti-cancer drugs have been rationally designed
to target a subset of patients with breast cancer: women
whose tumours over-express a protein named human
epidermal growth factor receptor-2 (HER-2Neu). One of
these medications, trastuzumab, a monoclonal antibody,
has recently been shown to decrease recurrences and
mortality by 50% in patients with early breast cancer trea-
ted with surgery followed by chemotherapy, radiotherapy
and hormonal therapy when appropriate [4,5]. It is there-
fore the first targeted agent that may cure patients with
breast cancer. Adverse events are usually mild but this
new medication comes with a high price tag.
In order to assess if a health care payer (government sys-
tem, insurance company or self-paying patient) should
approve the use of the drug, this study aimed to evaluate
the societal costs and benefits of treatment with Trastuzu-
mab in patients with early breast cancer in Singapore and
to discuss policy implications.
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While there are no clinical studies performed in the
Singapore setting to confirm the survival and recurrence
prevention benefits seen with trastuzumab in the United
States and Europe, available evidence suggests that those
results can be extrapolated to the island nation. This is
the first study to assess the cost-benefit of trastuzumab
in early breast cancer in Singapore [6].
Methods
Literature Search
A systematic search of the medical and health economics
literature using the MEDLINE/PUBMED and EMBASE
databases and the Johns Hopkins University Library
system (supplemented by manual reading of review arti-
cles in search for further references) revealed three studies
which evaluated the cost utility of trastuzumab given con-
currently with paclitaxel chemotherapy following 4 cycles
of an anthracycline and cyclophosphamide (The most
common current standard of care worldwide and in Singa-
pore). Details of the search(es) were as follows, (a). Terms
used: trastuzumab, cost-effectiveness, cost-utility, cost-
benefit, adjuvant, early breast cancer in MESH terms and
with several permutations; (b). Results: trastuzumab AND
cost-effectiveness (or cost-benefit) retrieved 50 citations.
Review of these citations revealed the three studies
included in this paper as mentioned above and also: 11
studies that assessed a strategy of trastuzumab following
chemotherapy (and not concurrent and then following as
is the current standard in Singapore), several other studies,
including budget impact papers, studies of other drugs and
several review articles.
Health Benefits
The three detailed cost-utility analyses published by Liber-
ato et al [7], Kurian et al [8] and Garrison et al [9] form
the basis of the health benefits data used in this report as
the quality adjusted life year (QALY) benefits for trastuzu-
mab are derived from their models. Other clinical benefits
are derived from the 3 clinical trials that set trastuzumab
as the new standard of treatment for patients with HER2-
Neu-expressing early breast cancer: HERA, NSABP B31
and NCCT 9831 [4,5].
Assumptions from each of the datasets: Kurian et al,
Liberato et al and Garrison et al can be seen in their
original papers and in additional file 1.
In summary they used Markov models to estimate the
long term health outcomes, quality of life and costs from
treatment with trastuzumab with results presented as
incremental cost-effectiveness ratios (ICER), in cost per
QALY saved for the following populations receiving adju-
vant therapy with or without trastuzumab. In addition,
Kurian et al assessed a non-anthracycline-containing
trastuzumab (NAT) regimen.
Kurian et al showed that in their base case analysis,
treatment without trastuzumab (NT) yielded 9.35 QALYs
at a cost of US$133,429, the anthracycline-containing
trastuzumab (AAT) regimen yielded 10.77 QALYs at a
cost of US$190,092, and the non-anthracycline-contain-
ing regimen (NAT) yielded 10.61 QALYs at a cost of US
$206,561. Compared with the NT regimen, the AAT
regimen yielded an ICER of US$39,892/QALY. The AAT
regimen dominated the NAT regimen (meaning that it
cost less and was more effective). Liberato et al calculated
that adjuvant trastuzumab resulted in a benefit of 1.34
life-years and 1.54 QALYs with an incremental cost of
€15,476 (US$20,211) for adjuvant trastuzumab and an
incremental discounted cost effectiveness of €14,861/
QALY (US$18,970/QALY). Garrison et al determined
that treatment with trastuzumab cost an additional US
$44,923 and had an expected gain of 1.70 QALYs.
Costs
All costs and benefits are incremental, i.e., they only
include the added expenses or gains associated with the
use of trastuzumab beyond those related to other treat-
ments. The author used Microsoft Office Excel 2007
(Microsoft Corporation, Redmond, WA, United States of
America) to determine net present values (NPV) with dis-
counting as described under general assumptions below.
Direct costs were obtained with a private patients’ per-
spective through a survey of treatment charges for the
hypothetical base case at 4 cancer centers in Singapore:
two government hospitals and 2 private institutions.
Together, these institutions provide treatment to 60-70%
of patients with cancer treated in Singapore (Personal
communication).
These costs are expressed as a weighted average per
number of new patients seen yearly. The weights were:
4,200 for restructured hospital number 1; 900 for restruc-
tured hospital number 2; 600 for private medical centre
number 1; and 200 for private medical centre number 2.
These are the estimated numbers of new patients with
cancer seen yearly at each institution.
Incremental direct costs comprised all medication and
infusion expenses related to treatment with chemotherapy
and trastuzumab in the adjuvant setting. Costs associated
with primary local, regional (radiation and surgery) and
systemic (chemotherapy) treatment were not included. To
determine the base case dose of trastuzumab, the author
calculated the median and mean weight of a sample of 40
consecutive women receiving chemotherapy at one of the
hospitals to be 48 kg (Data not shown).
The following expenses, based on medical oncologist
opinions and discussions with the business offices of
each medical centre, were added to the calculation of
incremental direct costs associated with trastuzumab per
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patient: Her2Neu testing (assuming all patients were
tested for immuno-histochemistry and 30% for fluores-
cence in situ hybridization), trastuzumab for 1 year (drug
and infusion costs), 9 extra consultations with medical
oncologist, 4 echocardiograms to monitor heart function,
and the cost of treatment of cardiac toxicity (incidence
estimated at 4%, cost included 3-monthly cardiology vis-
its and medications for 1 year). The costs of excess can-
cer recurrence (local and distant) for patients who did
not receive trastuzumab (i.e., the direct benefits) were
subtracted from the costs of trastuzumab as they repre-
sent a cost saving in favour of the treatment.
The cost of local recurrence included fees for surgery
and hospital stay as well as treatment with trastuzumab
for 1 year multiplied by its predicted frequency. Standard
of care for patients who progress systemically on trastuzu-
mab included treatment with (a) capecitabine and lapati-
nib, or (b) capecitabine and trastuzumab. Once patients
progressed they received trastuzumab and lapatinib in
combination (c). The estimates assumed that patients
received 9 months of treatment with (a) or (b) followed by
3 months of treatment with (c)
Indirect costs were assessed as the loss of productivity
derived from absence from work for treatment (Derived
from Gross National Income per capita data). In addition,
the cost of transportation for each treatment was esti-
mated based on median mass transit fare in Singapore.
Benefits
Gross national income per capita (GNI/capita) was the
measure of individual productivity used to calculate the
benefits of treatment. Benefits to society were based on
extra years of productivity, resulting from the quality
adjusted life-years (QALYs) saved with the use of Tras-
tuzumab. As these were determined independently by
Liberato et al [7], Kurian et al [8] and Garrison et al [9],
the results section presents 3 sets of benefits, one from
each dataset.
Calculation of Societal Costs and Benefits
Societal costs (benefits) were estimated as the sum of
direct and indirect costs minus benefits. To account for
variability, 95% Confidence Intervals were calculated
based on the 95% confidence intervals for QALYs
gained from the datasets by Kurian and Liberato and
the range of possible QALYs are depicted for the results
derived from Garrison’s [7-9].
Other Assumptions
General Assumptions
This report uses GNI per capita estimates from the
International Monetary Fund for 2005 [10] values at
purchasing power parity. Euros and Singapore dollars
were converted to United States Dollars at the median
exchange rate in 2005 [11]. All future benefits and costs
were discounted at a 3% rate and represented as 2005
United States Dollars complying with the guidelines pro-
duced by the US Public Health Service Panel on Cost-
Effectiveness in Health and Medicine [12].
Gross National Income per capita was derived from
the International Monetary Fund and World Bank data
for 2005 at purchasing power parity [13,14].
United States Dollar to Euro median exchange rates
were derived from the European Central bank data [11].
Singapore Dollar to United States Dollar median exchange
rates were obtained from the Monetary Authority of
Singapore [15].
Results
Direct Costs and Benefits of Trastuzumab in the Treat-
ment of Early Breast Cancer in Singapore
Table 1 shows the costs associated with the use of
trastuzumab in the treatment of early breast cancer in
Singapore for the base case. Total incremental patient
costs without subsidies at the 2 government restructured
hospitals were S$ 51,040.63 and S$ 35,462.94 (govern-
ment hospitals have different purchasing contracts for
many cancer drugs, likely explaining the difference
between them). Not surprisingly costs were higher at
the 2 private medical centres, at S$ 62,769.82 and S$
70,376.73. (All in 2009 Singapore dollars)
The weighted average of incremental direct costs were
S$ 50,512.63 in 2009 Singapore dollars and US$
34,130.16 in 2009 United States dollars. To allow for
international comparison and to comply with current
comparative effectiveness guidelines these values were S
$ 44,879.86 and US$ 26,971.05 in 2005 dollars.
Note that the largest ticket in all hospitals was the
cost of the drug which accounted for more than overall
costs before they were discounted by the benefits of
avoided recurrences. One should also mention that the
lowest cost provider charged patients nearly half of what
the highest cost provider did.
Indirect Costs
Indirect costs were calculated as productivity lost during
treatment and the cost of transportation to receive treat-
ment. Indirect incremental costs associated with the use
of trastuzumab in Singapore were 2005 US$ 932.97.
Indirect Benefits
Indirect benefits were determined as productivity gained
based on the QALYs saved with trastuzumab in the
treatment of early breast cancer in Singapore. They are
depicted for each of the previously discussed datasets.
Indirect Benefits Based on Liberato et al Dataset
In this model, chemotherapy alone yielded an increase of
8.03 QALYs compared to 9.22 QALYs when trastuzumab
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was added. As such incremental indirect benefits in pro-
ductivity (discounted annually at 3%) were the difference
between the extra productivity achieved in 9.22 years
(2005 US$ 243,847.69) minus that achieved in 8.03 years
(2005 US$ 216,023.08), namely 2005 US$ 27,824.60.
Indirect Benefits Based on Kurian et al (2007) Dataset
In Kurian’s model treatment with trastuzumab gener-
ated 10.77 QALYs versus 9.35 QALYs with chemother-
apy alone. As such, incremental indirect benefit was
calculated as 2005 US$ 31,898.05.
Indirect Benefits Based on Garrison et al (2007) Dataset.
Finally, Garrison et al calculated benefits of 11.78 and
10.08 QALYs with and without trastuzumab, yielding
incremental indirect benefit of 2005 US$ 37,167.08.
Societal Costs (Benefits) Associated with the Use of
Trastuzumab in Singapore
With the data presented above one can calculate the
societal costs (benefits) of trastuzumab in the treatment
of early HER2neu-positive breast cancer in Singapore
for each of the dataset as follows: Societal Costs (Bene-
fits) = Direct Costs + Indirect Costs - Indirect Bene-
fits. (Remember that indirect benefits are already
accounted in direct costs as seen in Table 1).
To account for variation and assess the precision of
this analysis, 95% confidence intervals were also calcu-
lated based on the 95% confidence interval of the
QALYs derived from each model. These data are repre-
sented in Table 2.
Based on Liberato et al
Assessment of societal costs (benefits) showed a cost of
2005 US$ 79.42 per patient associated with the use of
trastuzumab in Singapore. The 95% confidence interval
varied from a cost of US$ 16,854.97 to a benefit of US$
16,353.79 per patient treated. Cost per QALY was 2005
US$ 22,664.75.
Based on Kurian et al
This model yielded a societal benefit of 2005 US$
3,944.03 per patient treated with a 95% confidence inter-
val ranging from a cost of US$ 11,295.76 to a benefit of
US$ 22,213.99. Cost per QALY was 2005 US$ 18,993.70.
Based on Garrison et al
Finally, on the third model, society benefits were 2005
US$ 9,263.06 per individual treated, ranging from US$
227.30 to US$ 12,274.98. Cost per QALY was 2005 US$
15,865.32.
Sensitivity Analysis
At the lowest range of the sensitivity analysis, using
the highest cost, from private medical centre number 1
and the lowest QALYs gained (as in the model by
Liberato et al), treatment with trastuzumab in Singa-
pore costs 2005 US$ 10,685.78 per patient. At the
highest range, using cost data from government
restructured hospital 1 and the benefits in the model
by Garrison et al, treatment of early HER2neu-positive
breast cancer in Singapore yields a benefit of 2005 US$
17,298.79 per individual treated.
Table 1 Incremental Direct Costs and Benefits Associated with Trastuzumab in the Treatment of Early HER2neu-




PMC 1 PMC 2 GRH 1 GRH2
HER2neu testing 615.10 410.50 133.00 322.14
Trastuzumab
Direct Drug Costs 82,798.74 74,250.00 48,656.88 64,152.00
Administration Costs 4,500.00 3,870.00 1,289.70 1,908.00
Extra Visits with Oncologist 1,170.00 1,498.00 350.00 749.00
Cardiac Monitoring 1,300.00 1,572.00 410.60 1,349.24
Cost of Cancer Recurrence
Local Disease 12,500.00 12,500.00 12,353.00 12,059.75
Metastatic Disease 124,767.00 117,714.00 95,525.56 108,325.20
Cost of Cardiac Toxicity 2,015.20 3,214.00 759.60 322.00
Total Incremental Cost (S$) 70,376.73 62,769.82 35,462.94 51,040.63
Incremental Costs in Singapore S$ 50,512.63 US$ 24,130.16 (2009)
S$ 44,879.82 US$ 26,971.05 (2005)
Notes to Table 1: PMC, private medical centre. GRH, government restructured hospital. HER2neu testing included costs of immunohistochemistry for all patients
and fluorescence in-situ hybridization for 30% of patients. There were 12 extra visits with oncologist. Cardiac monitoring included 4 tri-monthly echocardiograms.
Cost of local recurrence included mastectomy and hospital stay. Standard of care for patients who progressed on trastuzumab included (1) capecitabine +
lapatinib, (2) capecitabine + trastuzumab and (3) trastuzumab + lapatinib. The estimate assumed that patients received 9 months of treatment with (1) or (2)
followed by 3 months of treatment with (3). Excess Local recurrence without trastuzumab is estimated at 1% and estimated distant recurrence at 16% based on
clinical trials. Cost of treatment of Cardiac toxicity was 4% × cost of 3-monthly cardiology visits + medications for 1 year.
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Discussion
In summary, based on the current study, treatment of
early HER2neu-positive breast cancer with trastuzumab
is associated with a small cost or a significant benefit
depending on the model used. Using the Liberato et al
dataset this paper described a cost of US$ 79.42 per
patient treated, contrasting with the larger benefits seen
with the models by Kurian et al (US$ 3,944.03) and
Garrison et al (US$ 9,263.06).
Moreover, the variance seen in the 95% confidence
intervals and sensitivity analysis is relatively narrow, ran-
ging from a highest societal cost of 2005 US$ 16,854.97
and a highest societal benefit of 2005 US$ 22,213.99 per
individual treated. While these results suggest that the use
of trastuzumab leads to societal benefits and support
payers in providing this treatment, this paper cannot rule
out that the targeted agent might actually lead to higher
costs than benefits in Singapore. The following discussion
will review the weakness and strengths of this study and
will provide a conclusion and recommendations aiming to
increase the potential societal benefits of trastuzumab in
the island-nation.
Health care in Singapore is financed by a mix of
compulsory health-savings accounts (Medisave), an
opt-out catastrophic insurance (Medishield) and gov-
ernment provision for patients without means (Medi-
fund). Moreover, the government provides means-
based subsidies that can reach up to 80% of hospital
expenditures. Public and private service providers com-
pete to provide affordable and world-class medical
services [16].
If not well planned, however, the limits on deduction
built in the Medisave system can lead to rationing and
not rationalization of medical care. As such, health eco-
nomics analysis of new technologies such as trastuzu-
mab should be undertaken to determine the most
efficient level of deduction for individual’s Medisave
accounts and to assist patients in understanding if there
is an individual and societal economic benefit in receiv-
ing the drug.
The first and major weakness of this study resides in the
use of previously published cost-effectiveness studies
instead of the development of an independent cost-effec-
tiveness model in Singapore. While one might argue that
this diminishes the applicability of this analysis, as the cur-
rent available clinical data is based on North-American
and Europe, a locally developed model would still have
health outcomes similar to the previously published ones.
Indeed the QALYs saved in the model by Liberato [7]
were identical in the United States and Italian settings.
Moreover, the use of 3 datasets - those by Liberato, Kurian
and Garrison and their colleagues [7-9], increases the
range of possible results, strengthening the applicability of
this analysis as the data presented are homogenous and
consistent.
The use of GNP per capita as a measure of productiv-
ity can also be criticized as it is not age and gender spe-
cific, introducing a possible source of bias. Moreover,
actual median wages in Singapore are lower than GNP
per capita further confounding the issue. Finally, it does
not take into account if a patient is employed - and
therefore productive. Despite these shortcomings, the
Table 2 Societal Costs (Benefits) Associated with Trastuzumab in the Treatment of HER2neu-positive Early Breast







Singapore Setting (This study)
Liberato et al 22,664.75 79.42 16,854.97 to (16,353.79)
Kurian et al 18,993.70 (3,944.03) 11,295.76 to (22,213.99)





Liberato et al 18,970.00 10,834.07 12,797.05 to (33,982.92)
Kurian et al 39,982.00 11,729.38 14,901.69 to 7,038.57
Garrison et al 26,417.00 n/a n/a
Italian Setting
Liberato et al 11,984.67 (1,287.63) 14,958.42 to (17,116.39)
Notes to table 2. Values are presented in 2005 US$ (unless otherwise stated) and represents costs (no parenthesis) or benefits (within parenthesis). Societal costs
and benefits derived from reference 6. n/a, not available. See text for further details.
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availability of GNI per capita data for several nations
allows for cross-country comparison and may aid in
decision-making as it is a measure commonly known by
policy makers.
A third weakness - or actually series of weaknesses -
has more to do with health economics assessments in
general than with this paper in particular. Methods
based on incremental costs often fail to account for the
resources used on standard therapy (in this case the
costs of local treatment, mastectomy and radiation ther-
apy, and systemic treatment with chemotherapy), and
might underestimate the actual resources employed.
Within the same group of limitations, one must note
that health economic models extrapolate long term hori-
zons from the short term data available from clinical
trials. As such, the benefits may become more or less
favourable over time, introducing another source of bias.
Further more, clinical trials have strict inclusion criteria,
making it harder to extrapolate data to usual popula-
tions seen in clinical practice.
Moreover, there are ethical issues that are beyond the
scope of this paper but involve the difficulty of assigning
a monetary value to a human life.
National settings are also important in the definition of
cost-effectiveness. In the United Kingdom, the National
Institute for Clinical Excellence [17] deems a new tech-
nology cost-effective if the cost per QALY saved is
30,000 British pounds or less; while in the United States
(where no agency is actually responsible for setting cost-
effectiveness standards) physicians and policy-makers
usually accept treatments that cost up to US$ 150,000 or
more per life year saved [18]. The World Health Organi-
zation considers interventions that are less than the
national income per capita as very cost-effective [19]).
In this paper, one assumes that interventions which gen-
erate economic benefits should be undertaken while those
that generate costs should be rejected, bringing us back to
the ethical issue of placing a monetary value on a human
life. This is one of the strengths of this study when
compared to the cost-effectiveness analyses conducted by
Liberato, Kurian, Garrison and their colleagues. The socie-
tal perspective in this analysis allows one to conclude that
trastuzumab is likely to generate economic benefits in the
treatment or early HER2neu-positive breast cancer in
Singapore.
One of the study’s strength is its use of charges that each
medical centre would impose to a patient with the base
case characteristics, through a survey of 4 centres which
together attend to 60-70% of patients with cancer in the
island-nation. Most economic analyses use published cost
data such as those from the Centres for Medicare and
Medicaid in the United States [20], potentially misrepre-
senting actual costs, as they do not usually include
overhead and other medical centre indirect costs such as
rental, personnel, etc.
Moreover, as mentioned above, using 3 published
cost-effectiveness studies to derive the health economic
benefits of trastuzumab, gives more strength to the con-
clusions as one sees the homogenous, consistent results
obtained with all 3 models.
Finally, it is interesting to compare the author’s prior
assessment of the societal costs and benefits associated
with trastuzumab in the US and European setting with the
current analysis. Based on the data from Liberato et al,
trastuzumab led to an incremental benefit of $10,834.07,
for which the 95% confidence interval ranged from a cost
of $12,797.05 to a benefit of $33,982.92 in the United
States setting. The corresponding values for Italy showed a
more modest benefit of 2005 US$ 1,287.63, with a 95% CI
ranging from a cost of $14,958.42 to a benefit of
$17,116.39.
The results based on the study by Kurian et al were
slightly different but not unexpected as their estimated
costs were higher. The incremental cost with trastuzu-
mab was 2005 US$ 11,729.38 (95% Confidence Interval,
$7,038.57 to $14,901.69).
These data contrast to the current study as the costs in
Singapore were lower than those in the United States and
Italy. Moreover, as the calculated incremental QALYs
saved were higher in the models by Kurian and Liberato,
these models yielded greater benefits in the current ana-
lysis. In the end, however all these results fall within a
relatively narrow band that goes from a highest cost of
2005 US$ 16,854.97 to a highest benefit of 2005 US$
22,213.99
As such, the current study’s limitations are offset by its
strengths and implications for the provision of health care
in Singapore and these data support Liberato, Kurian and
Garrison’s conclusions that therapy with trastuzumab in
the adjuvant setting is cost-effective in developed coun-
tries, although it might lead to greater societal costs than
benefits. Longer follow-up in the adjuvant trastuzumab
studies will help shed light on many of the uncertainties
seen in the data presented.
Our greatest challenge, however, is to broaden the reach
of these technological improvements both in underserved
populations in developed countries and in less affluent
nations. It is important that the medical oncology commu-
nity continues to promote societal discussion on health
economics topics, especially on the issue of treatment
access and affordability.
For now, civil society has helped increase access to the
drug in the island-nation and the government is broaden-
ing its actions. The Singapore Cancer Society, a charity
funded by private donations, helps provide subsidies ran-
ging from 25 to 75% of total drug costs to many needy
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patients and, recently, the Singapore government disclosed
that it will include trastuzumab in a new medication assis-
tance fund.
But we need to and can do better.
Available policy options range from government inter-
vention - which has its own set of problems - to more
market-oriented approaches (which the author favours).
For a lengthier discussion see reference [21]. In the spe-
cific case of Singapore, two sensible changes might suf-
fice to increase utilization of this clinically active and
cost-effective agent.
First, price discrimination (also known as tier-pricing)
should be employed and Roche (which now holds the
rights to sell trastuzumab) should consider decreasing the
price of the drug by approximately 15%-20%. As the cost
of trastuzumab is the largest element in the incremental
direct costs associated with its use this measure would
bring the lowest range of the sensitivity analysis closer to
zero increasing the likelihood that society would reap eco-
nomic benefits with the use of the targeted agent. As it
would also bring costs closer to current Medisave and
Medishield limits of deduction (approximately S$2,600 per
3-week cycle) it would likely increase revenues for the
pharmaceutical company as more patients would be able
to afford the drug.
Second, the government, through the ministry of health,
could consider tweaking the current Medisave system in
order to allow for a greater deduction from each indivi-
dual’s health savings account for the use of trastuzumab in
the treatment of patients with early HER2neu-positive
breast cancer in Singapore. This measure could also
increase the number of patients who would be able to
afford it, generating greater benefits to society.
Conclusion
Treatment with adjuvant trastuzumab is likely to gener-
ate net societal economic benefits in Singapore. Never-
theless, the lower range of possible outcomes does not
refute the possibility that treatment may actually gener-
ate costs. These costs however clearly fall within the
usual range of acceptable cost-effectiveness.
In the future, emerging clinical data might provide
information that shorter treatment duration is as effica-
cious as the current year-long course, while achieving
greater cost-effectiveness. In fact, a study named FIN-
HER demonstrated that the use of trastuzumab for 9
weeks decreases disease recurrence by 50%, similar to
the current standard of care [22]. Uncertainty remains
however as this was a relatively small study and it did
not have a comparator arm with trastuzumab given for
a year. Several studies are currently investigating shorter
durations of treatment with trastuzumab.
For now, the 2 suggestions described in this paper
may provide the best chance that more patients will be
able to benefit from trastuzumab in the treatment of
early HER2neu-positive breast cancer in Singapore.
Additional material
Additional File 1: Assumptions of each of the models by Liberato et
al, Kurian et al and Garrison et al.
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